The predictive biomarker of radio-therapeutic effect for cancer bone metastasis

2023 Fiscal Year Final Research Report

• Project/Area Number: 17KK0181
• Research Category: Fund for the Promotion of Joint International Research (Fostering Joint International Research)
• Allocation Type: Multi-year Fund
• Research Field: Radiation science
• Research Institution: Hirosaki University
• Principal Investigator: Monzen Satoru 弘前大学, 保健学研究科, 准教授 (20514136)
• Project Period (FY): 2018 – 2023
• Keywords: メタボローム / 放射線内用療法 / 癌骨転移 / 塩化ラジウム / 有害事象

Outline of Final Research Achievements

In castration-resistant prostate cancer, 80% of these cases proceed to bone metastasis with skeletal related events, resulting in reduced quality of life. To recover from this condition, alpha-emitting radionuclide therapy (223Ra) is widely used to combat bone metastasis from CRPC. However, numerous variances in both therapeutic effects and side effects have been reported. We found that phosphatidylcholine (PC) is a predictive biomarker for 223Ra treatment in these patients.In patient analysis, serum bone microemvironment markers, such as BAP and NTx, showed an alteration of individual variety. However, an up-regulated PC concentration of serum in good outcome was observed than poor outcome. PC that was detected in cell line model showed a similar trend in comparison to a clinical serum assay. These results suggest that PC production in prostate cancer cell exposed to ionizing radiation shows a dose-dependent mechanism associated with cell damage and cell death.

Free Research Field

放射線治療生物学

Academic Significance and Societal Importance of the Research Achievements

前立腺癌が世界で増加傾向にあり、それに伴い骨転移患者も増加している。治療方法は世界各地域で差があるものの、概ね骨代謝をコントロールする化学療法が施行される他、放射線内用療法が分子標的療法の選択肢としてある。しかしながら、その効果には個人差がある。本課題の成果は、放射線内用療法を推奨できる患者を選択する技術を提供するもので、この方法が応用できるならば、患者への治療選択の提供の最適化が可能となり、治療効果はもちろんの事、医療コスト削減、治療による有害事象リスクを低減することが可能となる。